Litigation Details for Pfizer Inc. v. Natco Pharma, Inc. (D. Del. 2021)

« Back to Dashboard

Pfizer Inc. v. Natco Pharma, Inc. (D. Del. 2021)

Docket		Date Filed	2021-10-19
Court	District Court, D. Delaware	Date Terminated	2022-09-20
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	11,065,250
Link to Docket	External link to docket

Details for Pfizer Inc. v. Natco Pharma, Inc. (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-10-19				External link to document

Pfizer Inc. v. Natco Pharma, Inc. | 1:21-cv-01466 Patent Litigation Summary

Last updated: August 18, 2026

Pfizer Inc. v. Natco Pharma, Inc., No. 1:21-cv-01466, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware involving Natco's proposed generic version of Pfizer's tafamidis product, marketed as Vyndaqel and Vyndamax. Pfizer asserted Orange Book-listed patents covering tafamidis pharmaceutical compositions and methods for treating transthyretin amyloidosis. The case was part of a broader generic challenge to Pfizer's tafamidis franchise and did not produce a public merits decision invalidating the asserted patents. [1]

What drug and patents were involved in Pfizer v. Natco?

The litigation concerned tafamidis, a transthyretin stabilizer used to treat transthyretin-mediated amyloidosis.

Item	Details
Brand products	Vyndaqel and Vyndamax
Active ingredient	Tafamidis, including tafamidis meglumine
Innovator	Pfizer
Proposed generic sponsor	Natco Pharma
FDA pathway	Abbreviated New Drug Application
Court	U.S. District Court for the District of Delaware
Case number	1:21-cv-01466
Case type	Hatch-Waxman patent infringement litigation
Primary therapeutic area	Transthyretin amyloidosis
Key patent issues	Composition, dosage form, pharmaceutical formulation and method-of-use protection

Pfizer's complaint followed Natco's filing of an ANDA containing a Paragraph IV certification against one or more patents listed for tafamidis products. A Paragraph IV certification states that a listed patent is invalid, unenforceable or would not be infringed by the proposed generic product. Filing the certification gives the innovator a statutory basis to sue under 35 U.S.C. § 271(e)(2). [2]

Public records identify the asserted estate as including Pfizer patents directed to tafamidis formulations and treatment methods. The case must be distinguished from earlier tafamidis patents that covered the underlying molecule and whose terms were materially shorter than later formulation and method-of-use patents.

What were Pfizer's infringement claims against Natco?

Pfizer's claims were based on the proposed commercial manufacture, use and sale of Natco's ANDA product. The complaint alleged that the generic product would infringe listed patents if approved and marketed.

The principal infringement theories in this type of tafamidis case were:

1. The generic dosage form would fall within claims directed to tafamidis or tafamidis meglumine compositions.
2. The proposed labeling would induce infringement of treatment methods for transthyretin amyloidosis.
3. Natco's ANDA filing constituted a technical act of infringement under the Hatch-Waxman statute.
4. Natco's product would compete with Vyndaqel or Vyndamax before expiration of the relevant patent claims.

Pfizer's economic objective was to preserve the commercial life of the tafamidis franchise beyond the expiration of earlier compound protection. The case therefore focused less on basic ownership of tafamidis and more on whether later-listed patents could delay generic approval or launch.

What patents protect Vyndaqel and Vyndamax?

The tafamidis patent estate has multiple layers. The earliest patents addressed the active compound or its therapeutic use. Later patents addressed salt forms, dosage strengths, formulations, dosing regimens and treatment of specific transthyretin amyloidosis populations.

Compound and early-use patents

The earliest tafamidis patents provided the initial exclusivity platform. Their terms were calculated from patent filing dates and were subject to any applicable patent-term adjustment or pediatric extension. These patents were not sufficient by themselves to explain the full duration of Pfizer's commercial protection for Vyndaqel and Vyndamax.

Formulation and dosage-form patents

Later patents covered pharmaceutical compositions containing tafamidis or tafamidis meglumine. Such claims can have greater commercial value than broad compound claims when the underlying molecule is approaching loss of exclusivity.

Formulation patents may cover:

• The active ingredient in combination with defined excipients.
• A particular salt or dosage form.
• Tablet composition and concentration ranges.
• Stability or dissolution characteristics.
• Administration of a specified daily dose.
• A formulation designed to achieve a particular pharmacokinetic profile.

Natco's Paragraph IV challenge likely required the court to evaluate claim construction, anticipation, obviousness and infringement based on the formulation disclosed in the ANDA.

Method-of-use patents

Method claims for transthyretin amyloidosis can create a second barrier to generic entry. An ANDA applicant may attempt to avoid infringement through a section viii statement that omits patented uses from the proposed label. That strategy is less effective when the remaining label still encourages use covered by the asserted method claims.

For Pfizer, method-of-use claims were commercially important because tafamidis is prescribed for defined disease populations and dosing protocols. The strength of these claims depends on the scope of the approved label, the wording of the claims and whether the generic label would encourage the patented use.

When does tafamidis lose exclusivity?

Tafamidis does not have one single loss-of-exclusivity date. The practical entry date depends on the patent challenged, the court outcome, any settlement, FDA exclusivity and the commercial scope of the generic approval.

Exclusivity layer	Commercial effect
New chemical entity exclusivity	Delayed ANDA approval during the statutory exclusivity period
Original tafamidis patents	Protected the active compound and early uses
Formulation patents	May extend protection for the marketed product or dosage form
Method-of-use patents	May restrict labeled use even after compound expiry
Pediatric exclusivity	Can add six months to qualifying patent or exclusivity periods
Patent litigation	Imposes a 30-month FDA approval stay after a timely suit

Under the Hatch-Waxman framework, Pfizer's timely infringement action triggered a statutory stay of FDA approval for the challenged ANDA, generally lasting 30 months unless terminated earlier by court order or another statutory event. [2]

The case therefore had near-term regulatory value even without a trial. A patent suit can postpone approval while the parties litigate or negotiate a launch date.

What was the Paragraph IV challenge in this case?

Natco's ANDA challenge put the validity and scope of Pfizer's listed tafamidis patents directly at issue. The relevant defenses in a Paragraph IV case generally include:

• Noninfringement because the ANDA product does not satisfy one or more claim limitations.
• Invalidity for anticipation under 35 U.S.C. § 102.
• Invalidity for obviousness under 35 U.S.C. § 103.
• Lack of written description or enablement under 35 U.S.C. § 112.
• Patent misuse or unenforceability, if supported by the record.

For formulation claims, the most important factual questions are usually the composition of the generic tablet, the concentration of excipients and the relationship between the ANDA specification and the patent claim language.

For method claims, the main question is whether Natco's proposed label would induce physicians or patients to practice the claimed treatment method. A generic applicant may reduce exposure by carving out patented indications, but the carve-out must remain consistent with FDA labeling requirements.

Did Pfizer v. Natco produce a patent trial or invalidity ruling?

The publicly available docket does not show a reported final judgment following a full merits trial that invalidated Pfizer's asserted tafamidis patents. The matter appears to have been resolved through procedural termination rather than a published opinion deciding the central validity issues. [1]

That distinction matters. A dismissal or stipulated resolution does not establish that the asserted patents were valid, enforceable or infringed. It also does not establish that Natco's product would have entered the market on the ANDA approval date.

The absence of a merits ruling leaves the broader tafamidis patent estate intact from a precedential standpoint. It also limits the value of the case as a guide to how a court would treat later-filed formulation or method patents.

Was there a settlement agreement between Pfizer and Natco?

The public docket indicates that the dispute ended without a publicly reported judicial determination on patent validity or infringement. The material commercial terms of any negotiated resolution were not disclosed in the public case record reviewed for this summary. [1]

If the parties resolved the dispute through a confidential settlement, the agreement may have established a permitted generic entry date, a license, a supply arrangement or another commercial compromise. Confidential settlement terms cannot be treated as evidence of the precise patent expiration date.

The absence of disclosed terms also prevents a reliable conclusion that Natco received an early-entry license, an authorized-generic arrangement or a specific launch date.

What is the FDA and Orange Book status of tafamidis?

Vyndaqel and Vyndamax are FDA-approved tafamidis products. Vyndaqel contains tafamidis meglumine, while Vyndamax contains tafamidis in a formulation intended to deliver tafamidis without the meglumine salt presentation. Both products are associated with Pfizer's transthyretin amyloidosis franchise. [3]

The FDA Orange Book identifies patents and regulatory exclusivities associated with approved products. Orange Book listings are central to Hatch-Waxman litigation because they determine which patents an ANDA applicant must address and which patents can trigger a 30-month stay after a Paragraph IV certification. [3]

Orange Book listing does not guarantee that a patent will survive validity scrutiny. It creates the statutory framework for notice, certification and litigation.

How strong is Pfizer's tafamidis patent estate?

Pfizer's tafamidis estate is stronger as a layered portfolio than as a single blocking patent.

Strengths

The portfolio has several commercial advantages:

• Multiple claim categories can cover the same product.
• Formulation claims can remain relevant after earlier compound claims expire.
• Method claims may constrain labeling and prescribing behavior.
• An ANDA filing triggers litigation and can delay approval.
• Tafamidis is a specialized product with a concentrated prescriber base, making label-based enforcement commercially meaningful.

Weaknesses

The principal risks are:

• Early compound patents have limited remaining life compared with later patents.
• Formulation claims can face obviousness challenges based on known salts, doses and excipients.
• Method claims may be vulnerable to a successful label carve-out.
• A generic applicant can challenge each patent separately through Paragraph IV certifications.
• A confidential settlement can establish an entry date that is earlier than the last nominal patent expiration.

The estate's practical strength depends on claim scope and the number of independent patents that cover the exact ANDA product. Patent count alone is an unreliable measure of blocking power.

What generic entry risks exist for Vyndaqel and Vyndamax?

The most important entry scenarios are:

Scenario	Effect on Pfizer
All asserted patents upheld	Generic entry may be delayed until the latest enforceable barrier expires
One key formulation patent invalidated	Natco may obtain approval earlier, subject to remaining patents
Method patent avoided through labeling	Partial generic entry may be possible
Settlement with licensed entry	Market entry occurs on the negotiated date
Patent expiration without further litigation	FDA may approve qualifying ANDAs subject to regulatory exclusivity
Multiple approved generics	Price erosion and accelerated share loss become more likely

Because tafamidis is a high-value specialty medicine, even limited generic competition could materially affect Pfizer revenue. The commercial impact would depend on whether the generic is approved for all labeled uses, whether multiple ANDAs are approved at the same time and whether Pfizer maintains payer access for the branded products.

Which companies challenged Pfizer's tafamidis patents?

Natco was one of several generic manufacturers associated with litigation against Pfizer's tafamidis patent estate. Other ANDA sponsors may have filed separate Paragraph IV certifications and faced related actions in the District of Delaware. Each case must be analyzed independently because defendants may challenge different patents, use different ANDA formulations or reach different settlements.

A multi-defendant litigation campaign increases the probability of a negotiated resolution but also raises the risk that one defendant will continue to litigate after others settle.

Key Takeaways

• Pfizer v. Natco, No. 1:21-cv-01466, was a Delaware Hatch-Waxman case involving generic tafamidis.
• The products at issue were Pfizer's Vyndaqel and Vyndamax.
• Pfizer relied on a layered estate covering tafamidis formulations and transthyretin amyloidosis treatment methods.
• Natco's Paragraph IV certification triggered patent litigation and a potential 30-month FDA approval stay.
• The case did not produce a reported merits decision invalidating Pfizer's asserted patents.
• Publicly available records do not disclose material settlement terms or establish a specific Natco launch date.
• Tafamidis generic-entry risk depends on the remaining formulation and method-of-use patents, not only on the earliest compound patent.
• The litigation preserved uncertainty around the timing of generic competition without creating a published precedent on Pfizer's patent validity.

FAQs

What was the drug in Pfizer Inc. v. Natco Pharma, Inc.?

The case involved tafamidis, the active ingredient in Pfizer's Vyndaqel and Vyndamax products for transthyretin amyloidosis.

Was Natco authorized to launch a generic version of tafamidis?

The public docket does not establish an unrestricted Natco launch authorization or disclose a definitive commercial launch date.

Did the court invalidate Pfizer's Vyndaqel patents?

No reported final merits decision in this case invalidated Pfizer's asserted tafamidis patents.

Does an Orange Book listing prove that Pfizer's patent is valid?

No. Listing supports the Hatch-Waxman certification and litigation process but does not determine patent validity or enforceability.

Can a generic tafamidis applicant avoid method-of-use patents?

Potentially. An applicant may use a section viii statement or label carve-out where FDA labeling permits omission of the patented indication. The strategy depends on the exact claim language and the proposed label.

References

1. U.S. District Court for the District of Delaware. (2021). Pfizer Inc. v. Natco Pharma, Inc., No. 1:21-cv-01466, docket records and pleadings.

2. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355; Patent Act, 35 U.S.C. § 271(e)(2).

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.